A Lexicon Prescription drugs drug that didn’t safe FDA approval in sort 1 diabetes underneath a partnership with Sanofi is now as a coronary heart failure remedy. The regulatory nod places the Lexicon tablet in competitors with medicines marketed by AstraZeneca and companions Eli Lilly and Boehringer Ingelheim.
Approval of the drug, sotagliflozin, covers adults who’ve had coronary heart failure and are susceptible to creating it once more. It additionally covers the discount of coronary heart failure threat in adults with sort 2 diabetes, continual kidney illness, or different cardiovascular threat components. Lexicon, based mostly in The Woodlands, Texas, will commercialize its new drug underneath the model identify Inpefa.
Inpefa follows a path blazed by medication that block sodium-glucose co-transporter sort 2 (SGLT2), a protein that permits kidneys to soak up glucose. By blocking this protein, SGLT2 inhibitors result in glucose being excreted within the urine. First accredited as therapies for diabetes, this drug class has two therapies which have secured further approvals in coronary heart failure: Farxiga from AstraZeneca and Jardiance from Lilly and Boehringer Ingelheim.
Lexicon executives imagine Inpefa matches up favorably towards each blockbuster merchandise. Whereas Inpefa is the third SLGT2 inhibitor accredited for coronary heart failure, Lexicon CEO Lonnel Coats mentioned his firm’s drug is the one one whose approval particularly contains the therapy of sufferers in transition from hospitalization to outpatient care.
“Inpefa’s broad label implies that now we have the flexibility to compete throughout your complete spectrum of coronary heart failure sufferers,” Coats mentioned, talking throughout a Tuesday convention name. “Nonetheless, our major focus can be on the candy spot of care, which for us is the transition-of-care affected person. We imagine that sufferers who’re stabilized following hospitalization for coronary heart failure are good candidates to be thought-about for Inpefa earlier than leaving the hospital or quickly thereafter.”
Along with blocking SLGT2, Inpefa additionally blocks SGLT1, a protein that’s liable for glucose absorption within the kidney. Lexicon found and developed the small molecule, advancing it to Part 3 testing in sort 1 diabetes. In 2015, on the drug, paying $300 million up entrance to realize international rights to the molecule. Lexicon continued to be liable for the drug’s medical growth.
In early 2019, the FDA turned down Lexicon’s software looking for approval of the molecule as a therapy for a sort 1 diabetes. Later that yr, Lexicon and Sanofi agreed to terminate the collaboration, and all rights to the molecule reverted to the biotech. Lexicon appealed the FDA’s rejection of the drug twice, however was denied each instances. The drug did go on to win approval in Europe for bettering glycemic management in adults with sort 1 diabetes when used along with insulin remedy.
FDA approval of Inpefa is predicated on the outcomes of two placebo-controlled Part 3 research, one enrolling sort 2 diabetes sufferers just lately hospitalized for worsening coronary heart failure and one other that evaluated the drug in sufferers with sort 2 diabetes, continual kidney illness, and dangers for heart problems. The drug met the objectives of each research. Tolerability of the tablet was akin to a placebo.
Jeffrey Wade, Lexicon’s president and chief monetary officer, mentioned Inpefa will profit from new American Coronary heart Affiliation and American School of Cardiology (ACC) pointers that advocate SLGT inhibitors as first-line therapies for coronary heart failure. An professional consensus assertion by the ACC particularly acknowledged that SLGT2 inhibitors needs to be used as soon as sufferers are stabilized. Wade famous that this standing is mirrored in Inpefa’s label.
Lexicon expects Inpefa, a once-daily tablet, will launch by the tip of June. The corporate shouldn’t be but disclosing the drug’s value, however Wade mentioned the wholesale value can be in step with the costs of different coronary heart failure medication available on the market now.
Magicmine, Getty Photographs